Introduction
Methods
AIMING FOR EFFICACY AND EFFECTIVENESS
Antipsychotic | Minimum effective doses in FEP (mg/day) | Oral/long acting | Advantages | Disadvantages |
---|---|---|---|---|
Haloperidol and other FGAs | 2 (haloperidol) | Several agents have long-acting injection forms | Overall efficacy in psychotic symptoms Best level of evidence | High risk of EPS, cognitive and depressive symptoms High risk of hyperprolactinemia Lower effectiveness compared to SGAs QTc prolongation (Haloperidol and other agents) |
Olanzapine | 5 | Long-acting injection form available | High mid- and long-term effectiveness compared to other antipsychotics Low risk of hyperprolactinemia | Very high risk of weight gain Very high risk of lipid and glucose disturbances Risk of sedation |
Risperidone | 2 | Oral and long-acting injection form available | High mid- and long-term effectiveness compared to other antipsychotics | Moderate risk of weight gain and lipid disturbances High risk of hyperprolactinemia Risk of EPS compared to other SGAs |
Quetiapine | 150 | Oral | Efficacy in several symptomatic domains Low risk of hyperprolactinemia | Very high risk of weight gain Very high risk of lipid and glucose disturbances Sedation Probably lower effectiveness compared to other SGAs |
Ziprasidone | 80 | Oral | Lowest risk of weight gain and neutral effect on glucose and lipids Low risk of hyperprolactinemia | Probably lower effectiveness compared to other SGAs QT prolongation |
Amisulpride | 400 | Oral | Efficacy and effectiveness | High risk of hyperprolactinemia Limited evidence in first episode psychosis |
Aripiprazol | 10 | Oral and long-acting injection form available | Low risk of weight gain and lipid and glucose disturbances Lowest risk of hyperprolactinemia Low risk of sedation | Risk of akathisia |
Paliperidone | 3 | Oral and long-acting injection form available | Low risk of sedation | Moderate risk of weight gain and lipid disturbances High risk of hyperprolactinemia Risk of EPS compared to other SGAs Limited evidence in first episode psychosis |
Clozapine | – | Oral | Greatest efficacy and effectiveness Efficacy in people with a FEP that do not respond to first-line antipsychotic treatment | Risk of weight gain and lipid disturbances. Agranulocytosis and cardiac risk Only for resistant patients |
Other SGA agents | No data available from FEP samples |